Plasma cell myeloma
Not recruitingStudy Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant
Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant
- Disease:Plasma cell myeloma
- Substances:CarfilzomibDexamethasone+3
Italy- Participants:18–64 years · 65+ years
- Substances:Carfilzomib
- Sponsor:Emn Trial Office S.r.l. Impresa Sociale










